About CSPC PHARMA Company

Shiyao Group Co., Ltd. (“Shiyao Group”) has a leading position in the pharmaceutical industry in China. The company was listed on the main board of the Hong Kong Stock Exchange in 1994. It is one of the well-known pharmaceutical listed companies in Hong Kong, China. It is currently one of the Hang Seng Composite Index, the Hang Seng Hong Kong Chinese Enterprises Index, and the Hang Seng Mainland China 100 constituent stocks. Shiyao Group has three major business segments: innovative drugs, general pharmaceuticals and APIs, and is mainly engaged in the development, production and sale of pharmaceuticals and related products. Proprietary pharmaceutical products mainly include antibiotics, cardiovascular drugs, antipyretic and analgesic drugs, digestive system drugs, antitumor drugs, and proprietary Chinese medicines. Among them, “embipp”, “olainin”, “xunning”, “domethoxin”, “zinyuli” and “nolinine” are innovative pharmaceutical products that sell well in China. API products mainly include antibiotics, vitamin C and caffeine series. The main production base of Shiyao Group is located in Shijiazhuang, Hebei, China. According to the evaluation by the World Brand Laboratory, one of the world's top five brand value evaluation agencies, the “Shiyao” brand has been selected as “China's 500 Most Valuable Brands” 11 times in a row since 2004. In terms of fulfilling its social responsibilities, the Shiyao Group has always taken the lead and has always enthusiastically supported social welfare undertakings. In activities such as SARS, the Indonesian tsunami, the Wenchuan earthquake, the Yushu earthquake, medical care for seriously ill children, and volunteering, etc. The Shiyao Group continues to give back to society with real things.